A Randomized Trial of Intraoperative, Intracisternal Tissue Plasminogen Activator for the Prevention of Vasospasm
- 1 July 1995
- journal article
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 37 (1) , 168-178
- https://doi.org/10.1227/00006123-199507000-00041
Abstract
A MULTICENTER, RANDOMIZED, blinded, placebo-controlled trial was conducted to study the possible role of intracisternally administered fibrinolytic agKeywords
This publication has 21 references indexed in Scilit:
- Prospective study on the prevention of cerebral vasospasm by intrathecal fibrinolytic therapy with tissue-type plasminogen activatorJournal of Neurosurgery, 1993
- Intracisternal recombinant tissue plasminogen activator after aneurysmal subarachnoid hemorrhageJournal of Neurosurgery, 1991
- Prevention of Vasospasm by Clot Removal and Intrathecal Bolus Injection of Tissue-Type Plasminogen Activator: Preliminary ReportNeurosurgery, 1991
- Effect of clot removal on cerebral vasospasmJournal of Neurosurgery, 1990
- Safety and Efficacy of Intrathecal Thrombolytic Therapy in a Primate Model of Cerebral VasospasmNeurosurgery, 1989
- Intrathecal Fibrinolytic Therapy after Subarachnoid Hemorrhage: Dosage Study in a Primate Model and Review of the LiteratureCanadian Journal of Neurological Sciences, 1989
- Effect of intrathecal thrombolytic therapy on subarachnoid clot and chronic vasospasm in a primate model of SAHJournal of Neurosurgery, 1988
- Modification of Experimental Post-Subarachnoid Hemorrhage Vasculopathy with Intracisternal PlasminNeurosurgery, 1988
- Modification of Experimental Post-Subarachnoid Hemorrhage Vasculopathy with Intracisternal PlasminNeurosurgery, 1986
- ASSESSMENT OF OUTCOME AFTER SEVERE BRAIN DAMAGE: A Practical ScalePublished by Elsevier ,1975